Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PLZRN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
sKB105
|
|||||
| Synonyms |
SKB105; PR023; CR-003
Click to Show/Hide
|
|||||
| Organization |
Kelun Biotherapeutics (Originator);Paragon Therapeutics;Crescent
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Anti-ITGB6 full human IgG1
|
Antibody Info | ||||
| Antigen Name |
Integrin beta-6 (ITGB6)
|
Antigen Info | ||||
| Payload Name |
TOP1 inhibitor
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Kthiol (pyrimidine-thiol) oligopeptide linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
2 Trials
|